plus_logo.png
Plus Therapeutics Presents Positive ReSPECT-LM Phase 1 Interim Data for Leptomeningeal Metastases at the 2024 SNO Annual Conference
25 nov. 2024 07h30 HE | Plus Therapeutics Inc.
Plus Therapeutics Presents Positive ReSPECT-LM Phase 1 Interim Data for Leptomeningeal Metastases at the 2024 SNO Annual Conference
plus_logo.png
Plus Therapeutics to Present Multi-Institutional Experience Using the CNSide™ Cerebrospinal Fluid Assay in Patients with Leptomeningeal Metastases
21 nov. 2024 07h30 HE | Plus Therapeutics Inc.
Plus Therapeutics to Present Multi-Institutional Experience Using the CNSide™ Cerebrospinal Fluid Assay in Patients with Leptomeningeal Metastases
plus_logo.png
Plus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
14 nov. 2024 16h15 HE | Plus Therapeutics Inc.
Plus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
plus_logo.png
Plus Therapeutics to Announce Third Quarter Financial Results and Host Conference Call on November 14, 2024
05 nov. 2024 07h30 HE | Plus Therapeutics Inc.
Plus Therapeutics to Announce Third Quarter Financial Results and Host Conference Call on November 14, 2024
SloanePRLogo.jpg
Sloane & Company Expands its Healthcare Practice with the Appointment of Managing Director Leslie Wheeler
15 oct. 2024 08h00 HE | Sloane & Company
NEW YORK, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Sloane & Company, a strategic communications firm at the intersection of valuation and reputation, announces the appointment of Leslie Wheeler as a...
plus_logo.png
Plus Therapeutics Reports ReSPECT-GBM Clinical Trial Update at the 2024 Congress of Neurological Surgeons Annual Meeting
01 oct. 2024 07h30 HE | Plus Therapeutics Inc.
Plus Therapeutics Reports ReSPECT-GBM Clinical Trial Update at the 2024 Congress of Neurological Surgeons Annual Meeting
plus_logo.png
Plus Therapeutics Showcases New Interim ReSPECT-GBM Phase 2 Trial Data at the 2024 Congress of Neurological Surgeons Annual Meeting
18 sept. 2024 07h30 HE | Plus Therapeutics Inc.
Plus Therapeutics Showcases New Interim ReSPECT-GBM Phase 2 Trial Data at the 2024 Congress of Neurological Surgeons Annual Meeting